|

U3-1402 Clinical Trials

1 actively recruiting trial

Also known as: HER3-DXd

Pipeline

Phase 2: 1

Top Sponsors

  • Gustave Roussy, Cancer Campus, Grand Paris1

Indications

  • Metastatic Breast Cancer1
  • Advanced Breast Cancer1
  • Breast Cancer1
  • Cancer1

Other1 trial

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.